The Benefits and Harms of Systemic Dehydroepiandrosterone (DHEA) in Postmenopausal Women With Normal Adrenal Function: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Context: Exogenous dehydroepiandrosterone (DHEA) therapy has been proposed to replenish the depletion of endogenous DHEA and its sulfate form, which occurs with advancing age and is thought to be associated with loss of libido and menopausal symptoms. Objective: We conducted a systematic review and meta-analysis to summarize the evidence supporting the use of systemic DHEA in postmenopausal women with normal adrenal function. Methods: We searched MEDLINE, EMBASE, PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus through January 2014. Pairs of reviewers, working independently, selected studies and extracted data from eligible randomized controlled trials (RCTs). We used the random-effects model to pool across studies and evaluated heterogeneity using the I2 statistic. Results: We included 23 RCTs with moderate to high risk of bias enrolling 1188 women. DHEA use was not associated with significant improvement in libido or sexual function (standardized mean difference, 0.35; 95% confidence interval, −0.02 to 0.73; P value = .06; I2 = 62%). There was also no significant effect of DHEA on serious adverse effects, serum lipids, serum glucose, weight, body mass index, or bone mineral density. This evidence warranted low confidence in the results, mostly due to imprecision, risk of bias, and inconsistency across RCTs. Conclusions: Evidence warranting low confidence suggests that DHEA administration does not significantly impact sexual symptoms or selected metabolic markers in postmenopausal women with normal adrenal function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systemic DHEA is not associated with significant improvement in libido or sexual function in postmenopausal women with normal adrenal function and cannot be recommended for women with HSDD 18 (Level IA, Grade A).”
From Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) · cites this paper as [18]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 3×
“Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing.”
MethodInfluentialPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 2×
“Between-study inconsistency was measured by I(2) statistics, which estimate the proportion of variation in results across studies that is not due to chance (19).”
BackgroundMethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 3×
“Statistical analysis Meta-analysis was done using random effect meta-analysis described by DerSimonian and Laird (22) to account for the The Endocrine Society.”
MethodInfluentialSterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 2×
“Publication bias Due to the small number of studies per each outcome, methods to detect publication bias could not be applied because these methods usually require at least 10 to 20 studies to reliably test for bias (23, 25).”
MethodAssessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · cited 1×
“Methodological quality and risk of bias assessment Two reviewers independently assessed the quality of each RCT using the Cochrane Risk of Bias assessment tool (20).”
MethodThe case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766 · cited 1×
“Publication bias Due to the small number of studies per each outcome, methods to detect publication bias could not be applied because these methods usually require at least 10 to 20 studies to reliably test for bias (23, 25).”
MethodORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349 · cited 1×
“The reduction in DHEAS is more prominent than that of T (2).”
Background
Cited by
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Androgen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2260 · Cited by 363
Self-citationThe physiology of endocrine systems with ageing
van den Beld, A. W., Kaufman, J.-M., Zillikens, M. C., Lamberts, S. W. J., Egan, J. M., & van der Lely, A. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30026-3 · Cited by 349
Menopause—Biology, consequences, supportive care, and therapeutic options
Davis, S. R., Pinkerton, J., Santoro, N., & Simoncini, T. (2023) · Cell · doi:10.1016/j.cell.2023.08.016 · Cited by 233
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01603 · Cited by 270
Clayton, A. H., Goldstein, I., Kim, N. N., Althof, S. E., Faubion, S. S., Faught, B. M., Parish, S. J., Simon, J. A., Vignozzi, L., Christiansen, K., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.11.002 · Cited by 226
Scavello, I., Maseroli, E., Di Stasi, V., & Vignozzi, L. (2019) · Medicina · doi:10.3390/medicina55090559 · Cited by 184
“Concerning other androgens, a recent meta-analysis showed that systemic treatment with DHEA was not effective in improving desire and sexual function in postmenopausal women with normal adrenal function [65].”
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
(2019) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003324 · Cited by 160
Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A. G. E., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., et al. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.10.009 · Cited by 182
“A meta-analysis in 2014 found that DHEA therapy did not improve sexual desire or other aspects of sexual function in postmenopausal women with normal adrenal function.(118) Therefore, oral DHEA cannot be recommended for the treatment of HSDD in postmenopausal women with normal adrenal function.”
The 2020 Menopausal Hormone Therapy Guidelines
Lee, S. R., Cho, M. K., Cho, Y. J., Chun, S., Hong, S.-H., Hwang, K. R., Jeon, G., Joo, J. K., Kim, S. K., Lee, D. O., et al. (2020) · Journal of Menopausal Medicine · doi:10.6118/jmm.20000 · Cited by 159
Sexual well-being after menopause: An International Menopause Society White Paper
Simon, J. A., Davis, S. R., Althof, S. E., Chedraui, P., Clayton, A. H., Kingsberg, S. A., Nappi, R. E., Parish, S. J., & Wolfman, W. (2018) · Climacteric · doi:10.1080/13697137.2018.1482647 · Cited by 127
Davis, S. R., Worsley, R., Miller, K. K., Parish, S. J., & Santoro, N. F. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2015.12.033 · Cited by 128
Managing the menopause: An update
Roberts, H., & Hickey, M. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.01.007 · Cited by 134
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Cerdas Perez, S., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., et al. (2019) · Climacteric · doi:10.1080/13697137.2019.1637079 · Cited by 113
The 2023 Practitioner’s Toolkit for Managing Menopause
Davis, S. R., Taylor, S., Hemachandra, C., Magraith, K. S., Ebeling, P. R., Jane, F., & Islam, R. M. (2023) · Climacteric · doi:10.1080/13697137.2023.2258783 · Cited by 106
Dehydroepiandrosterone Research: Past, Current, and Future
Klinge, C. M., Clark, B. J., & Prough, R. A. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.02.002 · Cited by 112
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
Prins, K. W., Thenappan, T., Weir, Ε. K., Kalra, R., PRITZKER, M. R., & Archer, S. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011343 · Cited by 80
Adrenal aging and its effects on the stress response and immunosenescence
Stamou, M. I., Colling, C., & Dichtel, L. E. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.10.006 · Cited by 81
Davis, S. R. (2024) · New England Journal of Medicine · doi:10.1056/nejmcp2313307 · Cited by 65
Global Consensus Position Statement on the use of Testosterone Therapy for Women
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Pérez, S. C., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I. V., LIU, J. H., et al. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.07.001 · Cited by 56
Kim, C., Dabelea, D., Kalyani, R. R., Christophi, C. A., Bray, G. A., Pi-Sunyer, X., Darwin, C. H., Yalamanchi, S., Barrett-Connor, E., Golden, S. H., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00967 · Cited by 54
Testosterone and Vaginal Function
Maseroli, E., & Vignozzi, L. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.03.003 · Cited by 57
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Pérez, S. C., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I. V., LIU, J. H., et al. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.07.012 · Cited by 56
Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A. G. E., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., et al. (2021) · Journal of Women s Health · doi:10.1089/jwh.2021.29037 · Cited by 57
“A meta-analysis in 2014 found that DHEA therapy did not improve sexual desire or other aspects of sexual function in postmenopausal women with normal adrenal function.(118) Therefore, oral DHEA cannot be recommended for the treatment of HSDD in postmenopausal women with normal adrenal function.”
Effect of Dehydroepiandrosterone (DHEA) on Diabetes Mellitus and Obesity
Aoki, K., & Terauchi, Y. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.01.008 · Cited by 51
Associations between androgens and sexual function in premenopausal women: a cross-sectional study
Zheng, J., Islam, R. M., Skiba, M. A., Bell, R. J., & Davis, S. R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30239-4 · Cited by 50
Tang, J., Chen, L.-R., & Chen, K.-H. (2021) · Pharmaceuticals · doi:10.3390/ph15010046 · Cited by 52
“Nonetheless, in postmenopausal women with normal adrenal functions, DHEA usage has no association with significant improvement in sexual function, quality of life, and general well-being [29].”
BackgroundMethodInfluentialThe Role of Cortisol and Dehydroepiandrosterone in Obesity, Pain, and Aging
Erceg, N., Mićić, M., Forouzan, E., & Knežević, N. N. (2025) · Diseases · doi:10.3390/diseases13020042 · Cited by 49
Androgens in postmenopausal women: a review
Shifren, J. L., & Davis, S. R. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000903 · Cited by 48
Jutel, A., & Mintzes, B. J. (2017) · Routledge eBooks · doi:10.4324/9781315399584-22 · Cited by 41
Irwig, M. S., Fleseriu, M., Jonklaas, J., Tritos, N. A., Yuen, K. C. J., Correa, R. R., Elhomsy, G. C., Garla, V. V., Jasim, S., Soe, K. K., et al. (2020) · Endocrine Practice · doi:10.4158/ps-2019-0540 · Cited by 41
“However, dermatologic and androgenic symptoms were reported in as many as 25% of patients (117).”
BackgroundHormonal profile of menopausal women receiving androgen replacement therapy: a meta-analysis
Marina, L., Šojat, A. S., Maseroli, E., Spaggiari, G., Pandurevic, S., & Santi, D. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01192-x · Cited by 35
“Conversely, systematic reviews and meta-analyses have found no statistically significant benefit of systemic DHEA on female sexual function; no significant effect of DHEA on serious adverse effects was observed either [15].”
BackgroundDehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period
Teixeira, C. J., Veras, K. M. D. A., & Carvalho, C. R. D. O. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01842-5 · Cited by 33
Should Dehydroepiandrosterone Be Administered to Women?
Wierman, M. E., & Kiseljak‐Vassiliades, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac130 · Cited by 37
Holloway, V., & Wylie, K. R. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000199 · Cited by 33
“However, a similar systematic review, this time looking at only postmenopausal women, found that DHEA had no impact on sexual symptoms compared with placebo [32].”
BackgroundDehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Štrac, D. Š., Konjevod, M., Perković, M. N., Tudor, L., Erjavec, G. N., & Pivac, N. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200317092310 · Cited by 31
Kershaw, V. F., & Jha, S. (2021) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12778 · Cited by 45
Dehydroepiandrosterone Stimulation of Osteoblastogenesis in Human MSCs Requires IGF‐I Signaling
Liang, X., Glowacki, J., Hahne, J., Xie, L., LeBoff, M. S., & Zhou, S. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25475 · Cited by 31
“…evidence suggests that DHEA administration does not significantly impact metabolic markers in postmenopausal women with normal adrenal function [Elraiyah et al., 2014], DHEA supplementation may be of benefit in two specific groups of women: those with the lowest circulating levels of DHEA and…”
BackgroundSauer, U., Talaulikar, V. S., & Davies, M. C. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.07.016 · Cited by 30
Dehydroepiandrosterone and Bone
Zhou, S., & Glowacki, J. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.01.005 · Cited by 33
Weiss, R. V., Hohl, A., Athayde, A. L., Pardini, D., Gomes, L. G., de Oliveira, M., Meirelles, R. M. R., Clapauch, R., & Spritzer, P. M. (2019) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000152 · Cited by 35
Lin, H.-Y., Chen, J.-H., & Chen, K.-H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178568 · Cited by 31
“However, in women receiving oral DHEA supplementation, it was found that DHEA was associated with no significant improvement in libido and sexual function [30,40].”
Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women
Elhassan, Y., Hawley, J. M., Cussen, L., Abbara, A., Clarke, S. A., Kempegowda, P., Dhillon‐Smith, R. K., Thadani, P., Busby, M., Owusu‐Darkwah, L., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.15265 · Cited by 31
“Ovarian testosterone secretion also declines into the perimenopausal phase of life with evolving ovarian failure, however this process is more gradual than that of oestrogen deficiency [30].”
Androgen-based therapies in women
Whitton, K., & Baber, R. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101783 · Cited by 25
Low Serum DHEAS Predicts Increased Fracture Risk in Older Men: The MrOS Sweden Study
Ohlsson, C., Nethander, M., Kindmark, A., Ljunggren, Ö., Lorentzon, M., Rosengren, B. E., Karlsson, M. K., Mellström, D., & Vandenput, L. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3123 · Cited by 25
“Modest positive effects of supplemental DHEA on BMD were reported in postmenopausal women, but a meta-analysis of seven studies indicated no significant effect of DHEA treatment on BMD in women.((17)) DHEA supplementation in adolescent and young women with anorexia nervosa, who characteristically have subnormal serum…”
BackgroundPotential therapeutic targets for sepsis in women
Weniger, M., D’Haese, J. G., Angele, M. K., & Chaudry, I. H. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1057570 · Cited by 22
“DHEA is a widespread overthe-counter drug and side effects are practically nil [94].”
BackgroundSexual health and wellbeing and the menopause: An EMAS clinical guide
Paschou, S. Α., Athanasiadou, K. I., Hafford‐Letchfield, T., Hinchliff, S., Mauskar, M., REES, M. C. P., Simon, J. A., Armeni, E., Erel, C. T., Fistonić, I., et al. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108055 · Cited by 21
Is Complementary and Alternative Therapy Effective for Women in the Climacteric Period?
Kim, M. Y., Choi, S. D., & Ryu, A. (2015) · Journal of Menopausal Medicine · doi:10.6118/jmm.2015.21.1.28 · Cited by 23
“In contrast, Elraiyah et al.(63) have recently suggested that DHEA is ineffective in improving sexual responsiveness and menopause symptoms.”
BackgroundProtective Role of DHEAS in Age-related Changes in Bone Mass and Fracture Risk
Yokomoto‐Umakoshi, M., Umakoshi, H., Iwahashi, N., Matsuda, Y., Kaneko, H., Ogata, M., Fukumoto, T., Terada, E., Nakano, Y., Sakamoto, R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab459 · Cited by 21
Mäntyselkä, A., Lindi, V., Viitasalo, A., Eloranta, A., Ågren, J., Väisänen, S., Voutilainen, R., Laitinen, T. P., Lakka, T. A., & Jääskeläinen, J. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00184 · Cited by 19
Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A. G. E., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., et al. (2021) · Climacteric · doi:10.1080/13697137.2021.1891773 · Cited by 20
“A meta-analysis in 2014 found that DHEA therapy did not improve sexual desire or other aspects of sexual function in postmenopausal women with normal adrenal function [118].”
MethodCollomp, K., Buisson, C., Gravisse, N., Belgherbi, S., Labsy, Z., Do, M., Gagey, O., Dufaÿ, S., Vibarel-Rebot, N., & Audran, M. (2018) · Endocrine · doi:10.1007/s12020-017-1514-z · Cited by 22
Jiménez, M. C., Tucker, K. L., Rodríguez, F., Porneala, B., Meigs, J. B., & López, L. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00205 · Cited by 17
Sexual Dysfunction in Men and Women
Bhasin, S., & Basson, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00020-4 · Cited by 19
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer
Pietri, E., Massa, I., Bravaccini, S., Ravaioli, S., Tumedei, M. M., Petracci, E., Donati, C., Schirone, A., Piacentini, F., Gianni, L., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0243 · Cited by 14
Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians
Cocchetti, C., Ristori, J., Mazzoli, F., Vignozzi, L., Maggi, M., & Fisher, A. D. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00409-8 · Cited by 15
Effect of dehydroepiandrosterone on atherosclerosis in postmenopausal women
Zhang, S., Zhou, J., Li, L., Pan, X., Lin, J., Li, C., Leung, W. T., & Wang, L. (2021) · BioScience Trends · doi:10.5582/bst.2021.01320 · Cited by 14
Pathophysiology and Medical Management of Hypoactive Sexual Desire Disorder
Clayton, A. H., & Vignozzi, L. (2018) · Wiley eBooks · doi:10.1002/9781119266136.ch6 · Cited by 15
Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy
Pofi, R., Bonaventura, I., Duffy, J., Maunsell, Z., Shine, B. S. F., Isidori, A. M., & Tomlinson, J. (2023) · Endocrine Connections · doi:10.1530/ec-23-0059 · Cited by 12
Ring, M. R. (2017) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.02.012 · Cited by 14
L'Hermite, M. (2017) · Climacteric · doi:10.1080/13697137.2017.1285277 · Cited by 11
DHEA replacement for postmenopausal women: have we been looking in the right direction?
Genazzani, A. R., & Pluchino, N. (2015) · Climacteric · doi:10.3109/13697137.2015.1042337 · Cited by 10
Changes in Muscle Mass and Bone Density and Their Relationship After Total Knee Arthroplasty
Heo, J., Koh, H.-S., Nam, C. H., Lee, D. C., Baek, J., Ahn, H. S., & Lee, S. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226700 · Cited by 10
“DHEA and DHEAS are associated with improved physical functions—such as muscle strength and bone density—as well as anti-inflammatory and immune-regulatory functions [6,7].”
Cardiovascular disease and female sexual health across the life span: a bidirectional link
Armeni, A. K., Armeni, E., Chedraui, P. A., & Lambrinoudaki, I. V. (2025) · Maturitas · doi:10.1016/j.maturitas.2025.108381 · Cited by 8
Androgens in postmenopausal women
Vigneswaran, K., & Hamoda, H. (2022) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12836 · Cited by 9
Female sexual dysfunctions: an overview on the available therapeutic interventions
LARA, L. A. D. S., RUFINO, A. C., OLIVEIRA, F. F., ROSSATO, S., BORGES, C. S., & REIS, R. M. (2022) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.22.04966-1 · Cited by 9
Kammerer-Doak, D., & Rogers, R. (2020) · Pelvic Floor Disorders · doi:10.1007/978-3-030-40862-6_74 · Cited by 3
Aging and the endocrine system
Jonas, M. I., Kuryłowicz, A., & Puzianowska‐Kuźnicka, M. (2015) · Postępy Nauk Medycznych · Cited by 9
Female Sexual Dysfunctions: A Clinical Perspective on HSDD, FAD, PGAD, and FOD
Graziottin, A., Maseroli, E., & Vignozzi, L. (2022) · Springer eBooks · doi:10.1007/978-3-031-11701-5_8 · Cited by 9
Pharmacotherapeutic options for the treatment of menopausal symptoms
Genazzani, A. R., Monteleone, P., Giannini, A., & Simoncini, T. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1921148 · Cited by 10
Sansone, A., & Romanelli, F. (2021) · Human Aging · doi:10.1016/b978-0-12-822569-1.00007-x · Cited by 5
Climacteric Symptoms: Importance and Management
Birkhaeuser, M. H. (2018) · ISGE series · doi:10.1007/978-3-319-63540-8_4 · Cited by 5
Astepe, B. S., & Köleli, I. (2018) · The European Research Journal · doi:10.18621/eurj.432490 · Cited by 7
The problem of female sexuality
Andreeva, E. N., & Sheremetyeva, E. V. (2019) · Russian Journal of Human Reproduction · doi:10.17116/repro20192503140 · Cited by 5
Current use of testosterone therapy in LGBTQ populations
Tijerina, A. N., Srivastava, A. V., Patel, V. R., & Osterberg, E. C. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00490-z · Cited by 5
“Despite conflicting evidence for low T as a cause of sexual dysfunction in women, TT in surgically or naturally menopausal cisgender women has shown to be a promising treatment [34].”
BackgroundClinical management of androgen excess and defect in women
Rosato, E., Sciarra, F., Minnetti, M., Degjoni, A., & Venneri, M. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2279537 · Cited by 4
“Studies using validated measures of sexual function have shown no improvement in libido and sexual function scores [161,172,173].”
BackgroundMethodAndrogene und weibliche Libido
Sartorius, G. A. (2017) · Gynäkologische Endokrinologie · doi:10.1007/s10304-017-0137-z · Cited by 4
“Da insbesondere Frauen in der frühen Postmenopause [16, 26] und Frauen nach beidseitiger Ovarektomie unter fehlender Lust leiden [28, 43], wurde die Hypothese entwickelt, dass der in diesen Situationen auftretende Sexualhormonmangel für den Libidoverlust verantwortlich sein könnte.”
BackgroundDHEA replacement for postmenopausal women: placebo or panacea?
Eden, J. (2015) · Climacteric · doi:10.3109/13697137.2015.1017706 · Cited by 4
Chen, S., Li, S., Zhang, X., Fan, Y., & Liu, M. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1272797 · Cited by 4
Imbalances in adrenal hormones and their effects on bone metabolism
Yokomoto‐Umakoshi, M., Umakoshi, H., & Ogawa, Y. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0117 · Cited by 2
“However, other studies found no significant associations [115-119], possibly due to insuf‐ ficient treatment duration or small sample sizes.”
Dehydroepiandrosterone in the ovarian insufficiency (a review)
Петров, И. А., Дмитриева, М. Л., Tikhonovskaya, O. A., Петрова, М. С., & Logvinov, S. V. (2016) · Russian Journal of Human Reproduction · doi:10.17116/repro201622624-32 · Cited by 2
Gebelerde cinsel fonksiyon değerlendirmesi: Serum androjen ve fetal cinsiyet ilişkisi
Astepe, B. S. (2019) · Zeynep Kamil Tıp Bülteni · doi:10.16948/zktipb.533351 · Cited by 2
Doping Status of DHEA Treatment for Female Athletes with Adrenal Insufficiency
Handelsman, D. J., Matsumoto, A. M., & GERRARD, D. F. (2016) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000300 · Cited by 3
Die „therapieresistente“ Libidostörung der Frau
Sarasin, E., & Leeners, B. (2018) · Gynäkologische Endokrinologie · doi:10.1007/s10304-018-0178-y · Cited by 1
“Die Behandlung mit Dehydroepiandrosteron (DHEA) hat einen leicht positiven Effekt auf die Libido in der Postmenopause [26], wird jedoch zum jetzigen Zeitpunkt für die Behandlung der weiblichen Luststörung bei funktionierender Nebennierenachse nicht empfohlen [27].”
BackgroundEndokrine Aspekte bei Libidostörungen
Keck, C. (2019) · gynäkologie + geburtshilfe · doi:10.1007/s15013-019-1768-z · Cited by 1
Holmes, D. T., & Kline, G. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818277-2.00018-2 · Cited by 1
Oğuz, S. H., & Yıldız, B. O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98804-9.00029-3 · Cited by 1
Androgen Replacement in Women: Safe and Efficacious?
Panay, N. (2015) · ISGE series · doi:10.1007/978-3-319-23865-4_12
Is vaginal administration the “way out” of the hormone of controversy?
Genazzani, A. R., & Pluchino, N. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000608
“Basic science studies, coupled with cross-sectional, observational, and randomized controlled trials, have shown that the evidence to support oral DHEA therapy in postmenopausal women is lacking and too imprecise.(1,2)”
BackgroundKim, C., Aroda, V. R., Goldberg, R. B., Younes, N., Edelstein, S. L., Carrion-Petersen, M. L., Ehrmann, D. A., & Diabetes Prevention Program Outcomes Study Group (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00244
The Use of DHEA to Improve Oocyte Quality
Kroon, B. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316756744.011
Sexualidad y climaterio: una mirada integral
Belardo, M. A., & Marina, G. (2016) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v36i1.691
Gibney, J., Banerjee, I., & Ho, K. K. Y. (2022) · doi:10.1093/med/9780198870197.003.0005 · Cited by 1
Yang, H., Ho, C., Zhao, P. T., Su, D., & Seftel, A. D. (2016) · Springer eBooks · doi:10.1007/978-1-4939-4928-1_12
Davis, S. R. (2023) · Climacteric · doi:10.1080/13697137.2023.2167598
Sexual Dysfunctions and Paraphilic Disorders
Rosen, N. O., Brotto, L. A., & Zucker, K. J. (2018) · Wiley eBooks · doi:10.1002/9781394258970.ch16
Long, C., Huang, C., Chang, C., Loo, Z.-X., Feng, C., Sung, I.-C., & Lin, K. (2026) · Gynecologic and Obstetric Investigation · doi:10.1159/000552775
Metadata
- Authors
- Elraiyah, T., Sonbol, M. B., Wang, Z., Khairalseed, T., Asi, N., Undavalli, C., Nabhan, M., Altayar, O., Prokop, L., Montori, V. M., & Murad, M. H.
- Affiliations
- Mayo Clinic (US)
- Augusta University (US)
- Knowledge and Evaluation Research Unit (T.E., M.B.S., Z.W., T.K., N.A., C.U., M.N., O.A., V.M.M., M.H.M.), Rochester, Minnesota 55905
- Corresponding author
- Murad, Mohammad Hassan
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-10-01
- Volume
- 99
- Issue
- 10
- Pages
- 3536-3542
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5393492
- OpenAlex
- W2026741948
- Cited by
- 97
- References
- 45
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 7 · 2021: 11 · 2020: 9 · 2019: 12 · 2018: 19 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 1
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000135)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- dehydroepiandrosterone, postmenopausal women, menopausal symptoms, sexual function, sexual desire, adrenal function, serum lipids, serum glucose, body mass index, bone mineral density, adverse effects
- MeSH terms
- Adjuvants, Immunologic, Adrenal Glands, Aging, Dehydroepiandrosterone, Female, Humans, Middle Aged, Randomized Controlled Trials as Topic, Postmenopause, Sexuality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.